Abdulrahman Katib: Factor XI Inhibitors as the Next Frontier in the Thrombosis Treatment Landscape
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
“Factor XI inhibitors are quickly becoming one of the most intensely studied drug classes in thrombosis medicine today.
What makes them so exciting is the possibility of achieving meaningful antithrombotic protection while preserving hemostasis — something we have been striving for in anticoagulation for decades.
That said, true clinical efficacy still needs to be firmly established in some of our highest-risk populations, particularly cancer-associated thrombosis (CAT), where thrombosis biology and bleeding risk coexist in a very delicate balance.
On a personal level, I was truly privileged to be part of the MAGNOLIA and ASTER trials.
Being involved in research at this stage — before results are known — is a unique experience. It reminds you that every future guideline, every future practice change, starts with patients, investigators, and teams working together to answer difficult clinical questions.
I am genuinely looking forward to seeing the final publications and understanding where Factor XI inhibition will ultimately position itself in our thrombosis treatment landscape.”
More posts about Abdulrahman Katib.
-
Sep 19, 2026, 03:15Paulus Kirchhof: Europe’s Safe Hearts Plan to Reduce Cardiovascular Mortality
-
Sep 19, 2026, 03:10James Smith: Brain Training and Exercise for Cognitive Recovery After Stroke
-
Sep 19, 2026, 03:03Lesley Van Wyk: ASH Releases New Iron Deficiency Diagnosis Guidelines
-
Sep 19, 2026, 02:53Francisco Chacón-Lozsán: Acute Ischemic Stroke in 2026 – Expanding the Treatment Window
-
Sep 19, 2026, 01:53Thomas Dayspring: Understanding Genome and Lipid Interactions in Lipidology
-
Sep 19, 2026, 01:47Abdurrahman Tufan: Combination Targeted Therapy in Refractory Systemic Autoinflammatory Diseases
-
Sep 19, 2026, 01:44Patrick James Lynch: Mother of a Thousand Sons Premieres at BDC 2026
-
Sep 19, 2026, 01:41Genetic Fate Mapping Reveals Endothelial Cells During Venous Thrombus Resolution – RPTH Journal
-
Sep 19, 2026, 01:39Mostafa Hammam: Three Different Platelet Defects – One Common Symptom